Immunovant (IMVT) Asset Writedowns and Impairment (2019)
Immunovant (IMVT) posted Asset Writedowns and Impairment of $230000.0 for Q4 2019.
Immunovant (IMVT) Asset Writedowns and Impairment (2019) Analysis & Trends
Immunovant's Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $230000.0 for Q4 2019.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $230000.0 in Q4 2019, while the trailing twelve-month figure through Mar 2021 was $230000.0 (changed N/A YoY) and the FY2020 annual result came in at $1.6 million, changed N/A from the prior year.
- Asset Writedowns and Impairment was $230000.0 for Q4 2019 at Immunovant.
- Across five years, Asset Writedowns and Impairment topped out at $230000.0 in Q4 2019 and bottomed at $230000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Immunovant | 7.39 Bn | 6.48 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 230,000.00 |
| Dec 31, 2019 | 230,000.00 |